Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
9 Meters Biopharma's larazotide patent positive in ALI/ARDS, says SunTrust » 10:50
07/28/20
07/28
10:50
07/28/20
10:50
NMTR

9 Meters Biopharma

$0.57 /

+0.0652 (+12.82%)

SunTrust analyst Srikripa…

SunTrust analyst Srikripa Devarakonda notes that 9 Meters Biopharma reported issuance of a patent for larazotide for potential treatment of acute lung injury and acute respiratory distress syndrome. The analyst says that the key takeaway is the potential relevance for use of larazotide in ALI/ARDS associated with COVID-19, with company currently evaluating potential pathways to develop larazotide either through internal research/out-licensing. However, data to date is either preclinical or based on computational models, Devarakonda adds. Overall, the analyst sees the patent as a positive for the company given promising preclinical data which indicate a potential role for larazotide in ALI/ARDS through its impact on tight junctions; potential role for larazotide in COVID-19 through inhibition of a key protease in the SARS-CoV2 virus as indicated by computational modeling; relevance of ALI/ARDS in COVID-19 and the challenges associated with addressing respiratory distress in COVID-19 patients. Devarakonda has a Buy rating and a price target of $5 on the shares.

ShowHide Related Items >><<
NMTR 9 Meters Biopharma
$0.57 /

+0.0652 (+12.82%)

NMTR 9 Meters Biopharma
$0.57 /

+0.0652 (+12.82%)

06/30/20 Truist
9 Meters Biopharma initiated with a Buy at SunTrust
06/30/20 Truist
9 Meters Biopharma initiated with a Buy at SunTrust
NMTR 9 Meters Biopharma
$0.57 /

+0.0652 (+12.82%)

Hot Stocks
9 Meters Biopharma issued larazotide-related patent from USPTO » 07:34
07/28/20
07/28
07:34
07/28/20
07:34
NMTR

9 Meters Biopharma

$0.51 /

-0.0028 (-0.55%)

9 Meters Biopharma…

9 Meters Biopharma announced the U.S. Patent and Trademark Office, or USPTO, issued U.S. patent No. 10,723,763, titled, Use of Tight Junction Antagonists in the Treatment of Acute Lung Injury and Acute Respiratory Distress, relating to its proprietary investigational agent, larazotide. The granted 9 Meters' patent shows, in a dose dependent fashion, larazotide renormalizes abnormally increased permeability of pulmonary tissue containing cellular tight junctions, and treats the direct cause of ALI and ARDS which can lead to fluid buildup within affected areas of the lungs. In pre-clinical models, larazotide has been shown to improve ALI as measured by protein, cellular and inflammatory markers, as well as suggest a protective effect in virally-challenged mice during infection, mitigating ALI by blunting pulmonary edema. Previous experiments have shown larazotide inhibits tight-junction rearrangement and prevents epithelial permeability triggered by gliadin, the antigen responsible for immunogenicity and symptoms in people with celiac disease. Furthermore, larazotide has been identified as a potential candidate in studies to target the main protease or Mpro also known as 3C-like protease of SARS-CoV-2, the virus responsible for COVID-19. Coupling this emerging data along with the molecule's known effects on epithelial and endothelial tight junctions, 9 Meters is evaluating potential next steps for future research to address the possible extended implications of larazotide for ALI/ARDS associated with COVID-19 for internal or out-licensing development.

ShowHide Related Items >><<
NMTR 9 Meters Biopharma
$0.51 /

-0.0028 (-0.55%)

NMTR 9 Meters Biopharma
$0.51 /

-0.0028 (-0.55%)

06/30/20 Truist
9 Meters Biopharma initiated with a Buy at SunTrust
06/30/20 Truist
9 Meters Biopharma initiated with a Buy at SunTrust
NMTR 9 Meters Biopharma
$0.51 /

-0.0028 (-0.55%)

Hot Stocks
9 Meters Biopharma doses first patients in Phase 1b/2a clinical trial in SBS » 07:51
07/21/20
07/21
07:51
07/21/20
07:51
NMTR

9 Meters Biopharma

$0.55 /

+0.0087 (+1.60%)

9 Meters Biopharma…

9 Meters Biopharma announced that the first patients have been dosed in a Phase 1b/2a clinical trial to assess NM-002 in adults with short bowel syndrome, or SBS. 9 Meters said in a release, "BS is a life-threatening orphan disease caused by a significant shortening of the gastrointestinal tract, leading to impaired nutrient absorption. Many SBS patients rely at least partly on parenteral support, an intravenous method of providing hydration, essential nutrients and electrolytes. NM-002 is a long-acting injectable glucagon-like peptide-1, or GLP-1, receptor agonist designed specifically to treat gastric motility in SBS patients by slowing digestive transit time, which may reduce reliance on parenteral support. The Phase 1b/2a clinical trial is an open-label, single-center study evaluating the safety and tolerability of three escalating doses of NM-002 in adult patients with SBS. Patients in each of three cohorts will receive two doses of NM-002 two weeks apart. Change in daily urine output volume is designated as the primary endpoint, as an inversely related proxy for usage of parenteral support. NM-002,which utilizes Amunix's proprietary XTEN technology to extend the circulating half-life of the GLP-1 peptide has demonstrated acceptable safety and a half-life of up to 30 days in a 70-patient clinical study and has been granted Orphan Designation by the FDA."

ShowHide Related Items >><<
NMTR 9 Meters Biopharma
$0.55 /

+0.0087 (+1.60%)

NMTR 9 Meters Biopharma
$0.55 /

+0.0087 (+1.60%)

06/30/20 Truist
9 Meters Biopharma initiated with a Buy at SunTrust
06/30/20 Truist
9 Meters Biopharma initiated with a Buy at SunTrust
NMTR 9 Meters Biopharma
$0.55 /

+0.0087 (+1.60%)

Conference/Events
9 Meters Biopharma participates in a conference call with BMO Capital » 10:25
07/09/20
07/09
10:25
07/09/20
10:25
NMTR

9 Meters Biopharma

$0.59 /

-0.0177 (-2.91%)

Healthcare Analyst…

Healthcare Analyst Nachman holds a conference call with President & CEO Temperato, CFO Sitar and CMO Griffin on July 9 at 11 am. Webcast Link

ShowHide Related Items >><<
NMTR 9 Meters Biopharma
$0.59 /

-0.0177 (-2.91%)

NMTR 9 Meters Biopharma
$0.59 /

-0.0177 (-2.91%)

06/30/20 Truist
9 Meters Biopharma initiated with a Buy at SunTrust
06/30/20 Truist
9 Meters Biopharma initiated with a Buy at SunTrust
NMTR 9 Meters Biopharma
$0.59 /

-0.0177 (-2.91%)

Conference/Events
9 Meters Biopharma participates in a conference call with BMO Capital » 04:55
07/09/20
07/09
04:55
07/09/20
04:55
NMTR

9 Meters Biopharma

$0.61 /

+0.0365 (+6.38%)

Healthcare Analyst…

Healthcare Analyst Nachman holds a conference call with President & CEO Temperato, CFO Sitar and CMO Griffin on July 9 at 11 am. Webcast Link

ShowHide Related Items >><<
NMTR 9 Meters Biopharma
$0.61 /

+0.0365 (+6.38%)

NMTR 9 Meters Biopharma
$0.61 /

+0.0365 (+6.38%)

06/30/20 Truist
9 Meters Biopharma initiated with a Buy at SunTrust
06/30/20 Truist
9 Meters Biopharma initiated with a Buy at SunTrust
NMTR 9 Meters Biopharma
$0.61 /

+0.0365 (+6.38%)

Over a month ago
Conference/Events
9 Meters Biopharma participates in a conference call with BMO Capital » 17:03
07/08/20
07/08
17:03
07/08/20
17:03
NMTR

9 Meters Biopharma

$0.61 /

+0.0365 (+6.38%)

Healthcare Analyst…

Healthcare Analyst Nachman holds a conference call with President & CEO Temperato, CFO Sitar and CMO Griffin on July 9 at 11 am. Webcast Link

ShowHide Related Items >><<
NMTR 9 Meters Biopharma
$0.61 /

+0.0365 (+6.38%)

NMTR 9 Meters Biopharma
$0.61 /

+0.0365 (+6.38%)

06/30/20 Truist
9 Meters Biopharma initiated with a Buy at SunTrust
06/30/20 Truist
9 Meters Biopharma initiated with a Buy at SunTrust
NMTR 9 Meters Biopharma
$0.61 /

+0.0365 (+6.38%)

Conference/Events
9 Meters Biopharma management to meet virtually with William Blair » 04:55
07/02/20
07/02
04:55
07/02/20
04:55
NMTR

9 Meters Biopharma

$0.72 /

+0.1405 (+24.40%)

Virtual Meetings to be…

Virtual Meetings to be held July 1-2 hosted by William Blair.

ShowHide Related Items >><<
NMTR 9 Meters Biopharma
$0.72 /

+0.1405 (+24.40%)

NMTR 9 Meters Biopharma
$0.72 /

+0.1405 (+24.40%)

06/30/20 Truist
9 Meters Biopharma initiated with a Buy at SunTrust
06/30/20 Truist
9 Meters Biopharma initiated with a Buy at SunTrust
NMTR 9 Meters Biopharma
$0.72 /

+0.1405 (+24.40%)

Conference/Events
9 Meters Biopharma management to meet virtually with William Blair » 04:55
07/01/20
07/01
04:55
07/01/20
04:55
NMTR

9 Meters Biopharma

$0.58 /

+0.0152 (+2.71%)

Virtual Meetings to be…

Virtual Meetings to be held July 1-2 hosted by William Blair.

ShowHide Related Items >><<
NMTR 9 Meters Biopharma
$0.58 /

+0.0152 (+2.71%)

NMTR 9 Meters Biopharma
$0.58 /

+0.0152 (+2.71%)

06/30/20 Truist
9 Meters Biopharma initiated with a Buy at SunTrust
06/30/20 Truist
9 Meters Biopharma initiated with a Buy at SunTrust
NMTR 9 Meters Biopharma
$0.58 /

+0.0152 (+2.71%)

Initiation
9 Meters Biopharma initiated with a Buy at SunTrust » 08:17
06/30/20
06/30
08:17
06/30/20
08:17
NMTR

9 Meters Biopharma

$0.56 /

+0.0305 (+5.75%)

SunTrust analyst Srikripa…

SunTrust analyst Srikripa Devarakonda initiated coverage of 9 Meters Biopharma with a Buy rating and $5 price target. The analyst is positive on the company's programs in Celiac Disease, or CED, and Short Bowel Syndrome, or SBS, noting that its "two shots on goal" with differentiated products represent a combined global peak sales unadjusted opportunity of about $1B. Devarakonda sees a "catalyst-rich" 12-18 month period for 9 Meters with its first PoC data in SBS and pivotal data in CeD, while also pointing to the company's "experienced management with over 50 years combined experience".

ShowHide Related Items >><<
NMTR 9 Meters Biopharma
$0.56 /

+0.0305 (+5.75%)

NMTR 9 Meters Biopharma
$0.56 /

+0.0305 (+5.75%)

06/30/20 Truist
9 Meters Biopharma initiated with a Buy at SunTrust
NMTR 9 Meters Biopharma
$0.56 /

+0.0305 (+5.75%)

Initiation
9 Meters Biopharma initiated with a Buy at SunTrust » 06:14
06/30/20
06/30
06:14
06/30/20
06:14
NMTR

9 Meters Biopharma

$0.56 /

+0.0305 (+5.75%)

SunTrust analyst Srikripa…

SunTrust analyst Srikripa Devarakonda initiated coverage of 9 Meters Biopharma with a Buy rating and $5 price target.

ShowHide Related Items >><<
NMTR 9 Meters Biopharma
$0.56 /

+0.0305 (+5.75%)

NMTR 9 Meters Biopharma
$0.56 /

+0.0305 (+5.75%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.